Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Bring in the cavalry

<< Previous

Bullboard Posts

Next >>

Comment by GoldenArmon Dec 06, 2021 11:04am

79 Views

Post# 34202142

RE:Bring in the cavalry

Yup seeing manipulation in a lot of stocks. Big reversal of the markets as well today whoever it is still early. I doubled up and got worried when it went down but held on. I was playing with house money but not anymore. The press and the results should propel this stock forward.

Key things to watch for is how long this study will take, how fast will the results be collated and presented.

Riverfolk, who is actually making the pills? Costs and revenues numbers would be good to.

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth